| NCT ID | NCT05950594 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University Health Network, Toronto |
| Condition | Soft Tissue Sarcoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 145 participants |
| Start Date | 2024-03-05 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 145 participants in total. It began in 2024-03-05 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Ability to understand and the willingness to sign a written informed consent document * Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension Exclusion Criteria: * Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05950594 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Soft Tissue Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05950594 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05950594 currently recruiting?
Yes, NCT05950594 is actively recruiting participants. Contact the research team at david.shultz@rmp.uhn.ca for enrollment information.
Where is the NCT05950594 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05950594 clinical trial?
NCT05950594 is sponsored by University Health Network, Toronto. The trial plans to enroll 145 participants.